“The global API manufacturing market is going through some major changes these days,” says Sean O’Brien, COO, Abzena. He ...

Just weeks after announcing a deal to sell its antibiotics manufacturing in the U.S. to Neopharma, India’s Dr. Reddy’s Laboratories says it will now unload its API manufacturing business in Jeedimetla ...

According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast projects the global active pharmaceutical ingredient market to expand from ...

EAST RUTHERFORD, N.J., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), ...

Eli Lilly and Company (Lilly) plans to construct an active pharmaceutical ingredient (API) manufacturing facility, totaling around 1 million square feet, in Harris County, Texas. According to news ...

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S.

Continuous Manufacturing for Small Molecule APIs Market · GlobeNewswire Inc. Dublin, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The "Continuous Manufacturing for Small Molecule APIs Market - Global Industry ...

The global industry was valued at US$ 38.9 Bn in 2022 and is expected to register a CAGR of 7.1% from 2023 to 2031. Demand for biologics, biosimilars, and other biopharmaceuticals is growing at a ...